EGRX - Eagle Pharma cleared of potential legal hurdle to launch generic for Endo's Vasostrict

Eagle Pharmaceuticals (EGRX +2.2%) announces that Par Pharmaceutical has unilaterally withdrawn its bid to block the launch of the company’s recently approved generic alternative to Vasostrict through a court ruling. Par owned by Endo International (ENDP -2.2%) had earlier requested the U.S. District Court for the District of Delaware to issue a temporary restraining order and preliminary injunction preventing the launch. While the company has withdrawn its request unilaterally, its appeal at the ruling issued by the District Court in favor of Eagle (NASDAQ:EGRX) on non-infringement of patents asserted by Par against Eagle remains pending. It “will continue to vigorously defend against such appeal,” Eagle (EGRX) said in a press release. With ~18.2% YoY growth, Vasostrict generated $676.8M in revenue for Endo (NASDAQ:ENDP) in the first nine months of this year.

For further details see:

Eagle Pharma cleared of potential legal hurdle to launch generic for Endo’s Vasostrict